When Is Cosentyx 150 mg Prescribed Every 2 Weeks?

Cosentyx (secukinumab) at 150 mg every two weeks is not the standard maintenance schedule listed on the drug’s label for most conditions, but it is a dosing pattern that comes up regularly in clinical practice. Doctors prescribe it for several reasons: body weight, incomplete response to monthly dosing, or the specific disease being treated. The evidence base for more frequent secukinumab dosing has grown considerably, and understanding when the every-two-week schedule makes sense can help you have a more informed conversation with your prescriber.

How Secukinumab Works and Why Dosing Frequency Matters

Secukinumab is a fully human antibody designed to block a protein called interleukin-17A (IL-17A), which drives inflammation in psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.¹ Like all biologic drugs, it gets cleared from your bloodstream over time. How quickly it clears depends largely on your body size: heavier patients dilute the drug into a larger volume, so levels drop faster between injections. That pharmacokinetic reality is the main reason some people end up on an every-two-week schedule rather than the every-four-week maintenance most labeling describes.

Exposure-response modeling has shown that the relationship between body weight and drug concentration is meaningful enough to warrant different schedules. Simulations suggest that lighter patients (around 50 kg) could maintain adequate drug levels with as little as 150 mg every four weeks, while patients weighing 120 kg or more may need the equivalent of 300 mg every three weeks to achieve comparable skin clearance.² This is why body weight sits at the center of nearly every conversation about dosing frequency adjustments.³

Evidence for Every-Two-Week Dosing in Heavier Psoriasis Patients

The strongest published trial data on every-two-week secukinumab comes from a randomized controlled study in psoriasis patients weighing 90 kg (about 200 pounds) or more. That trial directly compared maintenance dosing every two weeks against every four weeks. At 16 weeks, about 73% of patients on the every-two-week arm achieved a 90% reduction in psoriasis severity, compared with roughly 56% on the standard monthly schedule. The difference was statistically clear, with the more frequent dosing more than doubling the odds of achieving that level of clearance.⁴

The gap held up over a full year. At week 52, complete skin clearance was achieved by about 47% of the every-two-week group versus 27% of the monthly group. Quality-of-life scores told the same story: roughly two-thirds of the more frequently dosed patients reported their psoriasis had no impact on daily life, compared with under half of the monthly group.⁵ This trial was conducted using 300 mg (two 150 mg injections), but the underlying pharmacokinetic principle applies to 150 mg dosing as well: shortening the interval between injections keeps drug levels from dipping too low in patients with higher body mass.

The 150 mg Dose in Ankylosing Spondylitis

For ankylosing spondylitis (AS), 150 mg is often the starting and maintenance dose. The standard labeled schedule is every four weeks after the loading period, and much of the long-term data uses that interval. In the MEASURE 1 extension study, patients on secukinumab 150 mg maintained strong improvements through five years, with about 79% achieving at least a 20% improvement in disease activity and 65% achieving at least a 40% improvement.⁶ The MEASURE 2 study found similar durability, with half of patients reaching a 40% improvement benchmark at five years and about a quarter achieving partial remission.⁷

When a patient with AS isn’t responding well enough to monthly 150 mg, their rheumatologist has two main options: increase the dose to 300 mg every four weeks, or shorten the interval to every two weeks while keeping the dose at 150 mg. Three-year data from the MEASURE 3 trial showed that the 300 mg dose produced somewhat higher response rates than 150 mg, with about 75% and 68% of patients reaching the 20% improvement threshold, respectively.⁸ Some clinicians prefer keeping the dose at 150 mg and shortening the interval as an alternative strategy, particularly for patients who tolerate the current dose well and simply seem to lose benefit toward the end of their four-week cycle. There is no large randomized trial of 150 mg every two weeks specifically in AS, so this approach rests on pharmacokinetic reasoning and clinical judgment rather than direct head-to-head evidence.

Psoriatic Arthritis and Joint Disease

In psoriatic arthritis, the 150 mg dose is standard. The FUTURE 4 trial found that 150 mg produced meaningful joint improvement, with about 41% of patients achieving a 20% improvement in their arthritis score at 16 weeks compared with 18% on placebo.⁹ Long-term real-world data from Italy showed that patients on secukinumab for psoriatic arthritis maintained low disease activity at four years, with about 77% of treatment-naive patients achieving a minimal disease activity target. The drug retention rate at four years was about 66%, meaning roughly a third of patients switched to something else over that period.¹⁰

As with AS, the every-two-week schedule at 150 mg for psoriatic arthritis is an off-label clinical decision rather than a formally studied regimen. But it follows the same logic: maintaining higher trough drug levels for patients whose disease breaks through toward the end of their dosing interval.

Every-Two-Week Dosing in Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is the condition where every-two-week dosing has the most formal support, though the approved dose for HS is 300 mg rather than 150 mg. In the SUNSHINE and SUNRISE phase 3 trials, the every-two-week arm significantly outperformed placebo, with about 42-45% of patients achieving a clinical response versus 31-34% on placebo.¹¹ Response was sustained out to 52 weeks. If your doctor has you on 150 mg every two weeks for HS rather than the studied 300 mg, that could reflect insurance constraints, a stepping-stone approach, or a clinical decision based on your individual situation.

A Canadian drug agency review of secukinumab for HS noted that economic considerations play a role in dosing decisions. When the agency assessed the every-two-week schedule, it flagged the higher drug costs and noted that shifting some patients to every-four-week dosing would reduce the overall budget impact, though it was unclear how many patients would tolerate the less frequent schedule in practice.¹²

Dose Escalation When Standard Dosing Falls Short

Some patients simply do not respond adequately to the standard approved regimen. A case series of 25 patients with moderate-to-severe psoriasis who were escalated to higher or more frequent secukinumab doses found that more than half achieved meaningful clinical benefit. The escalated regimens were generally well tolerated.¹³ While a 25-patient case series is thin evidence, it reflects what many dermatologists and rheumatologists are already doing in practice: when 150 mg every four weeks isn’t cutting it, they try shortening the interval before switching drug classes entirely. The reasoning is straightforward. If a patient is partially responding but losing benefit toward the end of their cycle, the drug is working but not lasting long enough. Higher trough levels should help, and more frequent dosing is one way to get there.

Safety With More Frequent Dosing

The safety profile of secukinumab across all three major indications (psoriasis, psoriatic arthritis, and ankylosing spondylitis) has been studied for up to five years in pooled clinical trial and post-marketing data. Serious adverse events were uncommon and showed no clear pattern. Rates of opportunistic infections stayed below 0.2 per 100 patient-years of treatment, malignancy rates were no more than 1 per 100 patient-years, and major cardiovascular events occurred at a rate below 0.7 per 100 patient-years with no increase over time.¹⁴ Active tuberculosis was rare. No new safety signals emerged over the five-year observation window.

Real-world data from a six-year Italian psoriasis cohort reported adverse events in about 20% of patients, mostly mucocutaneous fungal infections and cardiovascular issues, though none were described as unexpected for a biologic-treated population.¹⁵ More frequent dosing increases total drug exposure, so in theory the risk of dose-dependent side effects rises modestly. However, the every-two-week psoriasis trial in heavier patients did not flag any disproportionate safety concerns compared to the monthly arm.

Candidiasis and Gut-Related Risks

The one side effect that deserves special attention with any IL-17 blocker is yeast infections. IL-17A plays a genuine role in the body’s defense against Candida, so blocking it tips the balance. Pharmacovigilance data show a roughly ten-fold higher reporting rate of candidiasis with IL-17 inhibitors compared with the background rate, with the strongest associations for oral and esophageal yeast infections. Compared to TNF-alpha blockers like adalimumab, the candidiasis reporting rate was about four times higher for skin yeast infections and about ten times higher for oral or esophageal infections.¹⁶ Most of these infections are mild and treatable with antifungals, but you should tell your doctor about any persistent white patches in your mouth, unusual vaginal symptoms, or difficulty swallowing.

A more contentious issue is the relationship between IL-17 blockade and inflammatory bowel disease (IBD). Research has suggested that inhibiting IL-17 may allow secondary overgrowth of Candida in the gut, which could trigger or worsen intestinal inflammation in susceptible individuals.¹⁷ This does not mean secukinumab commonly causes IBD, but if you have a personal or family history of Crohn’s disease or ulcerative colitis, your doctor will probably weigh this risk carefully before prescribing any IL-17 inhibitor. On more frequent dosing, any theoretical gut-related risk would track with overall drug exposure, so it is something to be aware of and monitor.

How Secukinumab Compares to Other Biologics

For ankylosing spondylitis patients trying to decide between secukinumab and a TNF blocker like adalimumab, head-to-head and indirect comparison data are informative. A matching-adjusted indirect comparison found no significant difference between secukinumab and adalimumab at 12 weeks, but by weeks 16 to 52, secukinumab showed a statistical edge on several measures of disease activity.¹⁸ A network meta-analysis including multiple biologics found secukinumab’s response rates in biologic-naive AS patients were generally similar to adalimumab, etanercept, and golimumab, though infliximab showed a statistically greater improvement in one disease activity measure.¹⁹

A head-to-head randomized trial comparing secukinumab 150 mg and 300 mg against an adalimumab biosimilar in radiographic axial spondyloarthritis looked at structural damage over two years. The proportion of patients with no new radiographic progression was virtually identical across all three arms, around 66%. Mean progression of spinal damage scores was also similar.²⁰ So the choice between the two drug classes often comes down to other factors: whether you have concomitant IBD (which favors a TNF blocker), how you feel about injection frequency, and how your insurance handles coverage.

Staying on the Drug Long-Term

Drug persistence, meaning how long patients keep taking the same biologic before switching, is one of the more practical measures of whether a medication is actually working in real life. A six-year Italian psoriasis study found that about 87% of patients were still on secukinumab at two years, dropping to roughly 66% at six years.²¹ Turkish real-world data from psoriasis patients showed similar early retention, about 94% at one year and 88% at two years, though it fell more steeply after year three to about 53% by year four.²² The reasons people discontinue vary: loss of efficacy over time, side effects, or sometimes practical issues like cost.

Being on every-two-week dosing may actually improve persistence if the more frequent schedule keeps drug levels adequate and prevents the end-of-cycle flare that drives some patients to switch. On the other hand, injecting twice as often carries a practical burden. If you find yourself losing motivation to keep up with biweekly injections, it is worth discussing with your doctor whether a switch to 300 mg every four weeks might achieve similar exposure with half the injection frequency.

Immunogenicity Is Rarely a Problem

One concern with any biologic is that your immune system might develop antibodies against the drug itself, potentially reducing its effectiveness over time. With secukinumab, this turns out to be a minimal issue. A five-year study of psoriasis patients found that treatment-emergent anti-drug antibodies appeared in a small fraction of patients, half the cases were transient (meaning the antibodies appeared briefly and then disappeared), and even in patients who developed neutralizing antibodies, there was no detectable effect on how well the drug worked, how safe it was, or how it moved through the body.²³ This low immunogenicity is one reason secukinumab can be used without a companion immunosuppressant like methotrexate, unlike some older biologics.

Vaccines While on Secukinumab

If you are on secukinumab, whether at a two-week or four-week interval, you can generally receive inactivated vaccines without concern. A study specifically testing the influenza vaccine in patients on secukinumab found no impairment of the immune response. Patients mounted normal antibody responses to all three influenza strains tested.²⁴ Live vaccines are a different story and are generally avoided during biologic therapy, so talk to your doctor about timing if you need something like a shingles vaccine (Shingrix, the recombinant version, is not live and is generally considered safe on biologics) or travel vaccinations.

Pediatric Patients and 150 mg Dosing

Secukinumab is also used in children and adolescents with moderate-to-severe plaque psoriasis, where the dose is weight-based and 150 mg (or 75 mg in smaller children) is the typical amount. In a phase 3 pediatric trial, about 93% of children at both dose levels achieved a 75% reduction in psoriasis severity at 12 weeks, with around 69-76% achieving a 90% reduction.²⁵ Safety reviews in pediatric populations have found no serious or unexpected adverse events, and the drug’s safety profile in children mirrors what has been seen in adults.²⁶ Dosing intervals in pediatric patients follow the standard schedule, though an adolescent with high body weight could face the same pharmacokinetic considerations as an adult, making more frequent dosing a conversation worth having with their pediatric dermatologist.